Skip To Main Content
Nancy L. Bartlett on Muck Rack

Nancy L. Bartlett

As seen in: Nature, Wiley Online Library, Taylor & Francis Online, The New England Journal of Medicine, The Lancet, Cell Press, Cancer Discovery, Journal of Clinical Oncology, Blood, Texas Medical Center and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nancy L.

Contact Nancy L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

|
By Martin Hutchings, Michael H. Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, William D. Townsend, Francesc Bosch, Nancy L. Bartlett, Guillaume Cartron, Herve Ghesquieres, Roch Houot, Harriet Walter, Fritz Offner, Natalie Dimier, Candice Jamois, Sylvia Herter, Sabine Wilson, Heather Hinton, Koorosh Korfi, Georgios Kazantzidis, Katharina Lechner, Franck Morschhauser, Abiraj Keelara, Jeremy Gallien, Isabel Prieto Gonzalez-Albo, Marie-Hélène Wasmer
| Nature Verified
Abstract There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Part 2 of the current study was an open-label, nonrandomized, phase 1 study of escalating doses of the CD19–4-1BBL co-stimulatory molecule, englumafusp alfa, in combination with glofitamab in patients with relapsed or refractory B-NHL. Obinutuzumab pretreatment was administered 7 days before the first glofitamab dose.
Open in Who Shared Issue with article?

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary

|
By Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett
| Taylor & Francis Online
Plain Language Summary What is this summary about? This summary shares results from part C of a study called SGN35-027. In this part of the study, researchers looked at treatment with the combination of 4 medicines called brentuximab vedotin (BV), nivolumab, doxorubicin, and dacarbazine. In this summary, this treatment is called the BV combination. The BV combination was studied in people with early-stage classical Hodgkin lymphoma (cHL).
Open in Who Shared Issue with article?

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

|
By Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline
| Wiley Online Library Verified
1 Introduction Many patients with follicular lymphoma (FL) experience disease relapse after initial therapy, with decreasing progression-free survival (PFS) after multiple lines of treatment [1-3]; therefore, effective novel therapies are needed to improve survival outcomes for patients with relapsed/refractory (R/R) FL.
Open in Who Shared Issue with article?
See all 27 licensed articles (28 Total)